Insulin Resistance-Improving Agent

1 . A method for improving insulin resistance, which comprises administering to a patient in need thereof an insulin resistance-improving agent comprising a pharmaceutically acceptable anion exchange resin as an active ingredient.

2 . The method according to claim 1 , wherein the pharmaceutically acceptable anion exchange resin has a bile acid-adsorbing ability.

3 . The method according to claim 1 , wherein the pharmaceutically acceptable anion exchange resin is selected from the group consisting of colestimide, cholestyramine resin, colestipol, sevelamer hydrochloride, and colesevelam hydrochloride.

4 . The method according to claim 1 , wherein the pharmaceutically acceptable anion exchange resin is an anion exchange resin synthesized by a polymerization reaction of an epichlorohydrin derivative and an amine of which typical example includes an imidazole derivative.

5 . The method according to claim 1 , wherein the pharmaceutically acceptable anion exchange resin is colestimide.

6 . The method according to claim 1 , with which an oral hypoglycemic agent is used simultaneously, separately, or successively.

7 . The method according to claim 6 , wherein the oral hypoglycemic agent is selected from the group consisting of α-glucosidase inhibitors, biguanides, insulin sensitivity improving agents, sulfonylurea agents, rapid-acting insulin secretagogues, pharmaceutical preparations comprising GLP-1 or derivatives thereof, and DPP-IV inhibitors.

8 . A method for suppressing the onset of or treating insulin resistance syndrome, which comprises administering to a patient in need thereof an onset-suppressing and/or therapeutic agent for insulin resistance syndrome comprising a pharmaceutically acceptable anion exchange resin as an active ingredient.

9 . The method according to claim 8 , wherein the pharmaceutically acceptable anion exchange resin has a bile acid-adsorbing ability.

10 . The method according to claim 8 , wherein the pharmaceutically acceptable anion exchange resin is selected from the group consisting of colestimide, cholestyramine resin, colestipol, sevelamer hydrochloride, and colesevelam hydrochloride.

11 . The method according to claim 8 , wherein the pharmaceutically acceptable anion exchange resin is an anion exchange resin synthesized by a polymerization reaction of an epichlorohydrin derivative and an amine of which typical example includes an imidazole derivative.

12 . The method according to claim 8 , wherein the pharmaceutically acceptable anion exchange resin is colestimide.

13 . The method according to claim 8 , with which an oral hypoglycemic agent is used simultaneously, separately, or successively.

14 . The method according to claim 13 , wherein the oral hypoglycemic agent is selected from the group consisting of α-glucosidase inhibitors, biguanides, insulin sensitivity improving agents, sulfonylurea agents, rapid-acting insulin secretagogues, pharmaceutical preparations comprising GLP-1 or derivatives thereof, and DPP-IV inhibitors.

15 . A method for the prophylaxis, improvement or treatment of a disease or symptom resulting from insulin resistance, which comprises administering to a patient in need thereof a prophylactic, improving and/or therapeutic agent for a disease or symptom resulting from insulin resistance, which comprises a pharmaceutically acceptable anion exchange resin as an active ingredient.

16 . The method according to claim 15 , wherein the disease or symptom resulting from insulin resistance is selected from the group consisting of hyperinsulinism, abnormal lipid metabolism, arteriosclerosis, abnormal vascular endothelial function, coronary artery disease, cardiovascular disease, renal dysfunction, hypertension, fatty liver, type 2 diabetes, hyperuricemia, multiple risk factor syndrome, and gestational diabetes.

17 . The method according to claim 15 , wherein the disease or symptom resulting from insulin resistance is selected from the group consisting of hyperinsulinism, abnormal lipid metabolism, abnormal vascular endothelial function, coronary artery disease, cardiovascular disease, renal dysfunction, hypertension, fatty liver, type 2 diabetes, and hyperuricemia.

18 . The method according to claim 15 , wherein the disease or symptom resulting from insulin resistance is selected from the group consisting of hyperinsulinism, abnormal lipid metabolism, renal dysfunction, fatty liver, type 2 diabetes, and hyperuricemia.

19 . The method according to claim 16 , wherein the coronary artery disease or cardiovascular disease is myocardial infarction, cerebral infarction, or cerebral apoplexy.

20 . The method according to claim 16 , wherein the multiple risk factor syndrome is syndrome X, visceral fat syndrome, or metabolic syndrome.

21 . The method according to claim 15 , wherein the pharmaceutically acceptable anion exchange resin has a bile acid adsorbing ability.

22 . The method according to claim 15 , wherein the pharmaceutically acceptable anion exchange resin is selected from the group consisting of colestimide, cholestyramine resin, colestipol, sevelamer hydrochloride, and colesevelam hydrochloride.

23 . The method according to claim 15 , wherein the pharmaceutically acceptable anion exchange resin is an anion exchange resin synthesized by a polymerization reaction of an epichlorohydrin derivative and an amine of which typical example includes an imidazole derivative.

24 . The method according to claim 15 , wherein the pharmaceutically acceptable anion exchange resin is colestimide.

25 . The method according to claim 15 , with which an oral hypoglycemic agent is used simultaneously, separately, or successively.

26 . The method according to claim 25 , wherein the oral hypoglycemic agent is selected from the group consisting of α-glucosidase inhibitors, biguanides, insulin sensitivity improving agents, sulfonylurea agents, rapid-acting insulin secretagogues, pharmaceutical preparations comprising GLP-1 or derivatives thereof, and DPP-IV inhibitors.